Business
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
SAN DIEGO, February 02, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion
About this update from Acadia Pharmaceuticals Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":800,"height":307,"url":"https://media.zenfs.com/en/business-wire.com/a5422bb726f7d0ab80c6e938deb6c0f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8sgaclLVKcn5uxlp4.mK3Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a5422bb726f7d0ab80c6e938deb6c0f6","width":800,"height":307},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/oM5bm_iUNGATTe9IP6QWpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE2MDA7aD02MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a5422bb726f7d0ab80c6e938deb6c0f6","width":800,"height":307}},"lazy":false},{"type":"text","content":"- Company expects to receive a negative opinion following oral explanation feedback and intends to request re‑examination upon review of formal adoption.","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, February 02, 2026--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its Marketing Authorization Application (MAA) for trofinetide for the treatment of Rett syndrome, following its recent CHMP oral explanation. Subject to the outcome of the CHMP vote in February, Acadia intends to request a re-examination of the opinion by the CHMP upon its formal adoption.","length":554,"tagName":"p"},{"type":"text","content":""While the negative trend vote is disappointing and not what we hoped for, we believe the strong data that supported the approval of trofinetide for the treatment of Rett syndrome in the United States, Canada, and Israel speak to the meaningful benefits that trofinetide can deliver," said Catherine Owen Adams, Chief Executive Officer. "We now have more than 1,000 patients on active treatment globally, from newly diagnosed 2-year-olds to adults who have lived with their disease for decades. Our ongoing real-world experience study in the U.S. continues to show outcomes that closely mirror the impact observed in rigorous randomized clinical trials conducted across a broad age range. We look forward to working with the EMA and other stakeholders to advance trofinetide as an ...